The in vitro activity of Cabozantinib as first- and second-line agent in metastatic renal cell carcinoma

被引：0
|
作者：
Zaccagnino, Angela [1 ]
Vynnytska-Myronovska, Bozhena [2 ]
Stoeckle, Michael [1 ]
Junker, Kerstin [1 ]
机构：
[1] Saarland Univ, Dept Urol & Pediat Urol, Homburg, Germany
[2] Univ Saarland, Homburg, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 3期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
195
引用
收藏
页码：102 / 102
页数：1
相关论文
共 50 条
  • [31] AN ECONOMIC EVALUATION OF CABOZANTINIB VS. EVEROLIMUS IN THE SECOND-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA
    Hart, L. A.
    Carlson, J. J.
    VALUE IN HEALTH, 2017, 20 (05) : A111 - A111
  • [32] Cabozantinib as a second-line treatment option in hepatocellular carcinoma
    D'Angelo, Alberto
    Sobhani, Navid
    Bagby, Stefan
    Casadei-Gardini, Andrea
    Roviello, Giandomenico
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2020, 13 (06) : 623 - 629
  • [33] First-line Treatment Result Influence Second-line Regimen Selection in Targeted Therapy for Metastatic Renal Cell Carcinoma
    Li, Jian-Ri
    Yang, Cheng-Kuang
    Wang, Shian-Shiang
    Chen, Chuan-Shu
    Chiu, Kun-Yuan
    Cheng, Chen-Li
    Yang, Chi-Rei
    Ho, Hao-Chung
    Ko, Jiunn-Liang
    Ou, Yen-Chuan
    ANTICANCER RESEARCH, 2014, 34 (10) : 5643 - 5647
  • [34] Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
    Geczi, Lajos
    Bodoky, Gyorgy
    Rokszin, Gyorgy
    Fabian, Ibolya
    Torday, Laszlo
    PATHOLOGY & ONCOLOGY RESEARCH, 2020, 26 (04) : 2201 - 2207
  • [35] Second-Line VEGFR TKI Outcomes After First-Line Immune Checkpoint Blockade in Metastatic Renal Cell Carcinoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (12) : 10 - 11
  • [36] A NETWORK META-ANALYSIS OF EFFICACY OF FIRST-LINE AND SECOND-LINE THERAPIES FOR THE MANAGEMENT OF METASTATIC RENAL CELL CARCINOMA
    Heo, J. H.
    Park, C.
    Zivkovic, M.
    VALUE IN HEALTH, 2019, 22 : S56 - S56
  • [37] ECONOMIC EVALUATION OF EVEROLIMUS AS SECOND-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN GREECE
    Solakidi, A.
    Kourlaba, G.
    Kontovinis, L.
    Koutsoukos, K.
    Bournakis, E.
    Boutis, A.
    Syrios, J.
    Tzovaras, A.
    Michailidi, C.
    Kalogeropoulou, M.
    Maniadakis, N.
    VALUE IN HEALTH, 2016, 19 (07) : A732 - A732
  • [38] Novel therapeutic options for second-line therapy in metastatic renal cell carcinoma (Review)
    von Klot, Christoph-A. J.
    Merseburger, Axel S.
    Kuczyk, Markus A.
    MOLECULAR AND CLINICAL ONCOLOGY, 2016, 4 (06) : 903 - 908
  • [39] Cost-Effectiveness of Second-Line Treatments for Metastatic Renal-Cell Carcinoma
    Giuliani, Jacopo
    Bonetti, Andrea
    CLINICAL GENITOURINARY CANCER, 2019, 17 (02) : E258 - E262
  • [40] Coronary angiography: first- or second-line examination?
    Danchin, N
    Angioi, M
    Fattah, IA
    Jacquemin, L
    ANNALES DE CARDIOLOGIE ET D ANGEIOLOGIE, 1997, 46 (08): : 493 - 497
12345